No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
52 |
4. Check minimum number of eventsNone |
52 |
5. Include endpointsNone |
52 |
6. Filter based on genotype QC (FinnGen only) |
51 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Autoimmune polyglandular failure
based on the number of shared cases.
Similar with more cases:
- Polyglandular dysfunction
- Disorders of other endocrine glands
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Endocrine, nutritional and metabolic diseases
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 302 | 189 | 110 |
| Only index persons | 247 | 161 | 86 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 33.80 | 36.67 | 28.51 |
| Only index persons | 31.59 | 35.00 | 25.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 51 | 30 | 21 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 26.66 | 34.27 | 15.79 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 52
- Matched controls
- 520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
311.9
37.4
34
*
H02AA02
ATC
fludrocortisone; oral
+∞
36.9
31
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
35.5
30
*
E31.00
ICD-10 Finland
APECED syndrome
+∞
30.1
26
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
30.1
26
*
H03AA01
ATC
levothyroxine sodium; systemic
13.2
20.3
34
65
E31.08
ICD-10 Finland
Autoimmune polyglandular failure
+∞
18.9
17
*
106
Kela drug reimbursment
Hypoparathyroidism
+∞
17.7
16
*
A12AA04
ATC
calcium carbonate; oral
245.7
17.7
17
*
A11CC03
ATC
alfacalcidol; systemic
89.2
17.0
18
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
20.1
15.4
24
21
A10AE05
ATC
insulin detemir; parenteral
24.1
14.7
21
14
A11CC02
ATC
dihydrotachysterol; oral
+∞
14.2
13
*
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
169.2
13.1
13
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
8.1
13.1
27
61
E83.51
ICD-10 Finland
Hypocalcemia
+∞
13.0
12
*
103
Kela drug reimbursment
Diabetes, insulin-treated
8.0
12.8
27
62
A10AB04
ATC
insulin lispro; parenteral
20.5
12.7
19
14
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
7.7
12.6
29
73
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
152.4
12.0
12
*
A10AC01
ATC
insulin (human); parenteral
13.9
11.8
21
24
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
56.3
11.5
13
*
A10AB05
ATC
insulin aspart; parenteral
12.7
11.3
21
26
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
7.2
11.2
24
55
A10AE04
ATC
insulin glargine; parenteral
12.3
11.1
21
27
121
Kela drug reimbursment
Severe hypofunction of sexual glands
42.2
10.9
13
*
T89
ICPC
Diabetes insulin dependent
15.5
10.9
18
17
2581B
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[AUTOIMMUNE-POLYENDOCRINOPATHY-CANDIDOSIS-ECTOD DYST]
+∞
10.8
10
*
107
Kela drug reimbursment
Pernicious anaemia
+∞
10.8
10
*
A07AA02
ATC
nystatin; oral
18.6
10.5
16
12
SPAT1262
SPAT
Handing over of treatment supplies
7.1
9.7
19
39
E31.0
ICD-10 Finland
Autoimmune polyglandular failure
+∞
9.7
9
*
2581A
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[SYNDROMA SCHMIDT]
+∞
9.7
9
*
25510
ICD-8 Finland
Diseases of adrenal glands, Adrenal cortical hypofunction
+∞
9.7
9
*
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
24.1
9.5
13
7
B03BA03
ATC
hydroxocobalamin; parenteral
30.4
9.4
12
5
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.9
9.4
28
86
H04AA01
ATC
glucagon; nasal, parenteral
15.6
9.3
15
13
A01AB09
ATC
miconazole; local oral
13.0
9.1
16
17
A10AB01
ATC
insulin (human); parenteral
13.0
9.1
16
17
104
Kela drug reimbursment
Thyroid insufficiency
13.5
8.7
15
15
E83.50
ICD-10 Finland
Hypercalcemia
106.7
8.7
9
*
A12AA06
ATC
calcium lactate gluconate; oral
+∞
8.6
8
*
E31.01
ICD-10 Finland
Schmidt's syndrome
+∞
8.6
8
*
A01AB04
ATC
amphotericin B; local oral
21.7
8.5
12
7
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.8
8.4
21
54
SBA00
NOMESCO Finland
Microbiological examinations
40.3
8.4
10
*
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
13.2
8.1
14
14
WZC00
NOMESCO Finland
Treatment plan or consultation
5.3
8.1
32
121
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
22.7
8.0
11
6
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
53.3
8.0
9
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
12.3
7.9
14
15
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
16.8
7.8
12
9
WX002
NOMESCO Finland
Sedation and analgesia
9.5
7.8
16
23
B37.08
ICD-10 Finland
Other candidal stomatitis
92.8
7.6
8
*
E87.6
ICD-10 Finland
Hypokalaemia
19.4
7.6
11
7
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
12.9
7.6
13
13
E27.2
ICD-10 Finland
Addisonian crisis
+∞
7.5
7
*
J02AB02
ATC
ketoconazole; oral
24.2
7.5
10
5
E03.89
ICD-10 Finland
Other specified hypothyroidism
35.5
7.4
9
*
XCK10
NOMESCO Finland
Photography of fundus of eye
9.1
7.2
15
22
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
11.1
7.1
13
15
K29.4
ICD-10 Finland
Chronic atrophic gastritis
46.2
7.0
8
*
H3600, E103,
ICD-10 Finland
26.6
6.9
9
*
R50.9
ICD-10 Finland
Fever, unspecified
5.2
6.8
18
48
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
13.5
6.7
11
10
TPH04
NOMESCO Finland
Cathetrisation of vein
5.3
6.6
17
44
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
4.4
6.5
30
123
A10AE06
ATC
insulin degludec; parenteral
12.3
6.4
11
11
H01AC01
ATC
somatropin; parenteral
+∞
6.4
6
*
25219
ICD-8 Finland
Diseases of parathyroid gland, Hypoparathyreoidismus alius sive NUD
+∞
6.4
6
*
25810
ICD-8 Finland
Polyglandular dysfunction and other diseases of endocrine glands, Polyglandular dysfunction
+∞
6.4
6
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
6.4
6
*
C03CA01
ATC
furosemide; systemic
4.9
6.3
18
51
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
7.9
6.2
14
23
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
37
126
7.71
11.55
4.2
1.7
98.50
97.69
pmol/l
0.03
26
62
33
101
7.21
11.52
8.2
3.7
10.03
9.04
mg/mmol
0.07
26
62
38
143
7.16
10.33
11.3
5.1
34.74
36.76
g/l
2.05
38
138
39
151
7.33
10.25
37.9
9.4
1.14
1.21
mmol/l
3.08
39
139
36
145
5.82
8.59
12.5
14.3
1.24
1.21
inr
0.08
15
48
30
109
5.14
7.97
6.7
3.6
2.23
2.33
mmol/l
1.77
30
99
16
23
9.53
7.75
7.7
11.7
5.88
5.67
kpa
0.30
16
23
30
111
5.02
7.74
2.0
1.5
0.76
1.30
u/ml
—
9
26
18
34
7.52
7.36
10.6
11.9
102.72
104.56
mmol/l
0.74
18
34
19
54
4.97
6.63
3.5
1.7
—
—
—
0
0
23
77
4.56
6.55
2.6
1.3
17.77
19.60
nmol/l
0.26
23
69
14
22
8.28
6.40
12.6
11.5
25.36
24.93
mmol/l
0.09
14
22
42
233
5.17
5.81
13.8
7.0
8.82
6.59
mmol/l
3.22
42
217
28
122
3.81
5.34
8.3
2.4
—
—
—
0
0
7
5
15.84
4.72
11.3
1.0
59.14
64.20
%
—
7
5
8
9
10.23
4.45
8.1
8.6
24.00
23.26
mmol/l
—
8
9
7
6
13.19
4.41
3.4
1.3
—
—
—
0
0
7
6
13.19
4.41
3.4
1.2
—
—
—
0
0
8
10
9.20
4.23
8.9
4.6
66.71
64.36
%
—
8
10
7
7
11.29
4.14
3.1
1.4
23.63
25.51
mmol/l
—
7
7
9
15
7.00
4.01
7.0
12.6
25.56
24.39
mmol/l
—
9
15
28
141
3.14
3.96
4.3
3.0
20.75
20.72
ng/l
0.00
20
77
7
8
9.87
3.90
3.4
1.3
—
—
—
0
0
7
8
9.87
3.90
3.4
1.3
—
—
—
0
0
6
5
13.30
3.86
1.5
2.8
—
—
—
0
0
12
32
4.56
3.69
4.4
3.3
—
—
—
0
0
13
38
4.21
3.64
2.8
1.7
—
—
—
0
0
9
18
5.80
3.55
1.7
1.7
—
—
—
0
0
8
14
6.53
3.49
6.4
12.4
1.76
1.14
%
—
8
14
6
7
9.48
3.35
4.0
1.3
—
—
—
0
0
6
7
9.48
3.35
4.0
1.3
—
—
—
0
0
12
36
4.02
3.29
2.9
1.5
—
—
—
0
0
6
8
8.28
3.14
1.7
1.0
—
—
—
0
0
7
12
6.55
3.13
2.3
1.7
—
—
—
0
0
5
6
9.04
2.81
1.0
1.0
—
—
—
0
0
26
145
2.59
2.81
3.4
3.0
42.88
32.72
u/l
0.66
26
140
10
30
3.87
2.78
1.6
2.7
229.10
241.57
u/l
—
10
30
10
30
3.87
2.78
13.7
25.3
118.10
129.77
g/l
—
10
30
8
20
4.53
2.69
12.4
11.3
0.61
0.84
%
—
8
20
5
7
7.74
2.60
1.4
1.0
—
—
—
0
0
8
21
4.30
2.58
12.4
10.9
1.45
1.78
%
—
8
21
6
12
5.49
2.47
2.3
2.3
191.67
143.58
ng/l
—
6
12
6
13
5.06
2.34
1.8
1.2
1.47
0.24
ug/l
—
6
13
7
19
4.09
2.24
20.7
3.6
25.49
25.77
mmol/l
—
7
19
16
82
2.37
1.96
3.2
2.4
—
—
—
0
0
5
12
4.48
1.87
14.0
1.8
4.22
3.85
mmol/l
—
5
12
7
24
3.20
1.79
19.9
24.2
24.17
24.70
mmol/l
—
7
24
5
13
4.13
1.75
1.2
1.0
—
—
—
0
0
5
13
4.13
1.75
2.8
1.9
—
—
—
0
0
5
13
4.13
1.75
4.0
2.0
—
—
—
0
0
20
119
2.11
1.70
7.1
3.3
0.00
0.00
estimate
-0.00
11
41
5
15
3.57
1.56
4.0
1.3
52.80
33.13
nmol/l
—
5
15
26
175
1.97
1.56
2.8
3.0
—
—
—
0
0
5
16
3.34
1.47
3.8
1.7
79.20
89.06
%
—
5
16
5
17
3.14
1.39
1.6
1.7
—
—
—
0
0
0
33
0.00
1.21
0.0
1.5
—
—
—
0
0
14
87
1.83
1.00
1.8
1.5
—
—
—
0
0
6
28
2.29
0.95
1.2
1.0
—
—
—
0
0
9
52
1.88
0.82
2.3
2.5
6.00
4.44
umol/l
—
9
46
27
213
1.56
0.78
8.1
4.5
0.00
0.00
estimate
-0.00
11
40
5
94
0.48
0.75
1.4
2.4
—
—
—
0
0
23
177
1.54
0.73
7.0
3.1
—
—
—
0
0
27
216
1.52
0.71
7.0
3.2
0.00
0.00
estimate
-0.00
11
42
27
216
1.52
0.71
7.0
3.3
0.00
0.08
estimate
—
10
38
5
85
0.54
0.63
1.2
2.2
—
—
—
0
0
0
22
0.00
0.61
0.0
1.3
—
—
—
0
0
0
22
0.00
0.61
0.0
1.3
—
—
—
0
0
0
22
0.00
0.61
0.0
1.3
—
—
—
0
0
0
23
0.00
0.60
0.0
1.7
—
—
—
0
0
12
83
1.58
0.58
1.3
1.3
0.86
2.09
u/ml
—
5
43
12
83
1.58
0.58
5.2
4.3
0.94
1.90
ug/l
1.53
12
73
7
49
1.49
0.48
24.0
6.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
8
106
0.71
0.33
1.4
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
37
349
1.21
0.18
3.6
3.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
35.37
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_AUTOPOLYFAI and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_AUTOPOLYFAI.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_AUTOPOLYFAI – Autoimmune polyglandular failure
GWS hits: 3
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data